Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

The purpose of this randomized, double-blinded, placebo-controlled study is to test the hypothesis that administration of aprepitant will decrease the severity of pruritus in patients with Sèzary Syndrome.

Inclusion Criteria:

• Known Sezary Syndrome
• Pruritus uncontrolled by conventional treatment. Baseline visual analogue scale > 4.
• Age 18 through 80 years of age.
• Stable medication regimens for both Sezary Syndrome and pruritus for 3 months prior to study participation.

Exclusion Criteria:

• Known hepatic impairment (defined as liver function tests >3 times the upper limit of normal).
• Pregnancy (all women of child-bearing potential will undergo urine beta-hcg testing).
• Concurrent use of pimozide, terfenadine, astemizole, or cisapride.